Review article: the benefits of pharmacogenetics for improving thiopurine therapy in inflammatory bowel diseaseLaurent Chouchana, Xavier Roblin, Céline Narjoz et al.|Alimentary Pharmacology & Therapeutics|2011Cited by 164
Interindividual variability in dabigatran and rivaroxaban exposure: contribution of ABCB1 genetic polymorphisms and interaction with clarithromycinIsabelle Gouin‐Thibault, Marie‐Anne Loriot, Céline Narjoz et al.|Journal of Thrombosis and Haemostasis|2016Cited by 140
<i><scp>UGT</scp>1A1</i> genotype and irinotecan therapy: general review and implementation in routine practiceMarie-Christine Étienne-Grimaldi, Chantal Le Guellec, Jean‐Christophe Boyer et al.|Fundamental and Clinical Pharmacology|2015Cited by 110
Dépistage du déficit en dihydropyrimidine déshydrogénase (DPD) et sécurisation des chimiothérapies à base de fluoropyrimidines : mise au point et recommandations nationales du GPCO-Unicancer et du RNPGxMarie‐Anne Loriot, Marie-Christine Étienne-Grimaldi, Joseph Ciccolini et al.|Bulletin du Cancer|2018Cited by 108